structure, including myelination and axonal density. Mean magnetization
transfer ratio fell in 18 untreated MSers both in normal appearing grey (-0.25 pu/year, p < 0.001) and white
matter (-0.12 pu/year, p = 0.004). Conversely, mean magnetization
transfer ratio was stable in 20 alemtuzumab-treated patients (grey
matter: -0.01 pu/year, p = 0.87; white matter: -0.02 pu/year, p = 0.51).
The gradient difference in grey matter was 0.25 pu/year (p < 0.001)
after age-adjustment. These data suggest that in multiple sclerosis alemtuzumab protects against tissue damage in normal-appearing grey matter, perhaps by preventing new lesion formation.
“It looks as if Alemtuzumab is neuroprotective. This is a very important observation and if confirmed will be very good news for MSers and more evidence to support early aggressive treatment to prevent gray matter damage.”